MOVER · THU OCT 22 2026

Why BHVN rose 22.3% on Oct 22 2026: fda review acceptance

BHVN+22.3%on Thu Oct 22 2026

Biohaven Ltd. was up 22.3% on the day at $14.37, ranked #1 on 215× its usual five-minute volume, when TapeRank recorded this spike at 07:05 ET during the pre-market session.

THE DAY ON THE LIST · 1 EVENT

  1. 07:05 ET
    MOVER · PRE-MARKET

    $14.37 · ▲ 22.3% ON THE DAY · 215× 5M RVOL · RANK #1

    JUSTIFIEDCONFIDENCE5/5

    Biohaven is up 1.29% in the last five minutes while essentially flat on the session after announcing FDA acceptance of its Vyglxia resubmission for review. The catalyst establishes a Q1 2027 action goal and planned advisory committee review, making the modest move proportionate to a meaningful but non-approval regulatory update.

    WHYA 1.29% five-minute move on FDA acceptance and a future review milestone is small relative to the significance of the regulatory update.
    ANALYZED 07:02 ET · 3 MIN AGO · OPENAI/GPT-5.6-LUNA
    THE ROW AND SESSION LEVELS AT 07:05 ET
    LAST14.37
    DAY▲ 22.3%
    5 MIN▲ 17.88%
    5M RVOL215×
    5M $VOL$961K
    FLOAT*151.0M
    RANK#1
    SESSIONPRE-MARKET
    VWAP12.88
    HOD14.49
    LOD11.60
    OR HIGH—
    OR LOW—
    PREV CLOSE11.75
    PM HIGH14.49
    PM LOW11.60
    GAP▲ 21.28% (indicated)

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

    — MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO

THE SESSION

  • 09:30 ETOpened at $16.10, +37.0% on the previous close of $11.75
  • 09:35 ETRegular-session high, $16.54
  • 13:03 ETRegular-session low, $14.45
  • 15:59 ETLast trade of the regular session, $14.70, +25.1% on the previous close of $11.75
  • Volume: 17.3M shares in regular hours, 12.3M before the open

BHVN opened at $16.10 after trading up 37.0% from the previous close, then reached $16.54 early before reversing to a $14.45 low at 13:03 ET. It finished the regular session at $14.70, still 25.1% above the prior close, with no halts during the session. TapeRank read the move as justified by Biohaven’s announcement that the FDA accepted its Vyglxia resubmission for review, establishing a Q1 2027 action goal and planned advisory committee review; the 07:00 ET 8-K disclosed the regulatory update and related exhibits.

WRITTEN THU OCT 22 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

01
ECGSURGING 0:05
79.71
▼ 29.3%
▼ 1.41%
41.0×
FAD
$6.2M
51.1M*
STRETCHED
02
CAVASURGING 0:00
64.78
▲ 7.4%
▲ 1.30%
9.3×
ORBHODVWH
$11.6M
116.8M*
UNEXPLAINED
03
URGNSURGING 0:00
29.16
▼ 15.2%
▼ 1.29%
15.6×
FAD
$1.4M
48.9M*
JUSTIFIED
04
MPTISURGING 0:00
64.15
▼ 1.5%
▲ 0.96%
23.8×
VWH
$637K
4.3M*
UNEXPLAINED
05
LSPDSURGING 0:00
11.52
▲ 4.9%
▼ 1.24%
16.5×
ORB
$426K
133.3M*
UNEXPLAINED
06
CRCTSURGING 0:00
8.90
▲ 49.2%
▼ 0.72%
15.1×
GAPORBVWHEXT
$395K
54.7M*
STRETCHED
07
BROSSURGING 0:00
43.97
▲ 0.9%
▼ 0.91%
4.0×
FAD
$4.3M
137.9M*
UNEXPLAINED
08
LMRICOOLING 1:35
12.85
▲ 14.5%
▲ 1.06%
132×
ORBHODVWH
$1.7M
—
UNEXPLAINED
Open the full list